What is ABVX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 6.91B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ABVX?

P/E (TTM) is n/a and 52-week range is €60.45 to €139.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ABVX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ABVX?

The company profile lists net income (TTM) near -$508M, EPS (TTM) near -€5.82 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Abivax SA based, and what identifiers does Chartloom list?

The company context section lists headquarters in Paris, Ile-De-France, FR, 87.3M shares outstanding, ISIN FR0012333284 when available from company profile and filing metadata.

Abivax SA

$ABVX

Health Care · Biotechnology

IR Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

Abivax SA

$ABVX

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 68 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Employees

68

Website

www.abivax.com/

IPO

2015-06-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NYSE EURONEXT - EURONEXT PARIS

ISIN

FR0012333284

Headquarters

Paris, Ile-De-France, FR

Shares outstanding

87.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

45.42%

Browse other companiesFree AI scores and summaries for more stocks

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 68 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Employees

68

Website

www.abivax.com/

IPO

2015-06-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NYSE EURONEXT - EURONEXT PARIS

ISIN

FR0012333284

Headquarters

Paris, Ile-De-France, FR

Shares outstanding

87.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

45.42%